Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.20
-0.40 (-4.17%)
At close: Jun 20, 2025, 4:00 PM
9.21
+0.01 (0.11%)
After-hours: Jun 20, 2025, 7:20 PM EDT

Intellia Therapeutics Stock Forecast

Stock Price Forecast

The 20 analysts that cover Intellia Therapeutics stock have a consensus rating of "Buy" and an average price target of $36.6, which forecasts a 297.83% increase in the stock price over the next year. The lowest target is $10 and the highest is $68.

Price Target: $36.6 (+297.83%)
Analyst Consensus: Buy
Target Low Average Median High
Price $10 $36.6 $41 $68
Change +8.70% +297.83% +345.65% +639.13%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 556677
Buy 766777
Hold 666666
Sell 000000
Strong Sell 000000
Total 181718192020

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$30
Strong Buy Reiterates $30 +226.09% Jun 16, 2025
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$74$54
Strong Buy Maintains $74$54 +486.96% Jun 3, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$30
Strong Buy Reiterates $30 +226.09% May 29, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$30
Strong Buy Reiterates $30 +226.09% May 20, 2025
Wedbush
Wedbush
Hold
Reiterates
$10
Hold Reiterates $10 +8.70% May 19, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
57.69M
from 57.88M
Decreased by -0.32%
Revenue Next Year
50.74M
from 57.69M
Decreased by -12.04%
EPS This Year
-4.28
from -5.25
EPS Next Year
-4.07
from -4.28
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
57.99M33.05M52.12M36.28M57.88M57.69M50.74M89.39M
Revenue Growth
34.55%-43.01%57.69%-30.40%59.55%-0.32%-12.04%76.16%
EPS
-2.40-3.78-6.16-5.42-5.25-4.28-4.07-3.68
EPS Growth
--------
Forward PE
--------
No. Analysts
-----292819
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 220.5M 105.0M 384.3M
Avg 57.7M 50.7M 89.4M
Low 16.3M 6.9M 3.6M

Revenue Growth

Revenue Growth 20252026202720282029
High
281.0%
82.0%
657.3%
Avg
-0.3%
-12.0%
76.2%
Low
-71.8%
-88.1%
-93.0%

EPS Forecast

EPS 20252026202720282029
High -2.50 -2.27 -1.72
Avg -4.28 -4.07 -3.68
Low -4.96 -5.44 -5.20

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.